High clinical benefit in the treatment of type 1 diabetes in children (1 – 17 years) but no demonstrated clinical improvement compared to LEVEMIR (insulin detemir).

• TRESIBA has MA for the treatment of diabetes in adolescents and children from 1 year of age.

• Its non-inferiority has been demonstrated compared to insulin detemir in terms of HbA1c variation over 26 weeks, in combination with insulin aspart.

• No benefit in respect of safety, quality of life or convenience of use has been demonstrated.